Press Releases July 23, 2026 12:30 PM

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026

OPKO Health Announces Q2 2026 Financial Results Release and Conference Call on July 27, 2026

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
OPK

OPKO Health, a multinational biopharmaceutical and diagnostics company, will report its second-quarter 2026 financial results on July 27, 2026. The company's senior management will host a conference call and webcast to discuss the financial results and provide business updates and financial guidance.

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
OPK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OPKO Health will report its Q2 2026 financial results on July 27, 2026.
  • A conference call and webcast will be held the same day to discuss results and provide financial guidance.
  • OPKO is focused on delivering next-generation healthcare solutions in global markets across biopharmaceutical and diagnostics sectors.

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO’s senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Participants who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed through OPKO’s Investor Relations here.

A telephone replay will be available until August 3, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 6858214. A webcast replay will be available beginning approximately one hour after the completion of the live conference call through OPKO’s Investor Relations here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

Alliance Advisors IR
Vivian Cervantes, 973-873-7724
[email protected]


Risks

  • Uncertainty about the financial performance for Q2 2026 until results are released, which could impact investor sentiment.
  • Potential volatility in stock price following earnings depending on how actual results compare to market expectations.
  • Broader risks inherent to the biopharmaceutical and diagnostics industry such as regulatory approvals and market competition.

More from Press Releases

What Is OpenAI Actually Patenting? PatentVest Pulse Analyzes OpenAI's Patent Portfolio Jul 23, 2026 Parsons Expands Mission-Focused Product Portfolio Across Defense, Intelligence, and Infrastructure Jul 23, 2026 OKYO Pharma Announces Purchase of Shares by Director Jul 23, 2026 iPower Signs Non-Binding LOI for Proposed $6 Million GPU Deployment Jul 23, 2026 Westamerica Bancorporation Declares Quarterly Cash Dividend Jul 23, 2026